This is a summary of the European public assessment report (EPAR) for Lutathera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Lutathera. For practical information about using Lutathera, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2\), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP?NETs) in adults.
Therapeutic Area (MeSH)
ATC Code
V10XX04
ATC Item
N/A
Pharmacotherapeutic Group
Other therapeutic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
EMA Name
Lutathera
Medicine Name
Lutathera
Aliases
N/ANo risk management plan link.
